medigraphic.com
ISSN 0016-3813 (Print)

2010, Number 2

<< Back Next >>

Gac Med Mex 2010; 146 (2)

Sobrevida de los pacientes con astrocitoma de alto grado que expresan el antígeno Ki67, atendidos en un hospital de pediatría

López-Aguilar E, Sepúlveda VAC, Rioscovián-Soto AP, Gascón-Lastiri G, Rojas-Puentes F, Siordia-Reyes G, Diegopérez-Ramírez J, De la Cruz-Yáñez H, Barrientos-Salcedo C

Language: Spanish
References: 33
Page: 118-123
PDF size: 80.60 Kb.


ABSTRACT

Background: Pediatric patients with malignant gliomas and same histological diagnosis respond distinctly to treatment. It is thus necessary to determine other factors that may influence the response to treatment and survival. Over expression of the Ki67 protein has been associated with poor treatment response. The aim of this study was to determine if the expression of this antigen influences survival of patients treated for malignant gliomas in the CMN SXXI Pediatrics Hospital.
Methods: We included patients with anaplasic astrocitoma or glioblastoma multiforme seen at our hospital between 1995 and 2005. We determined the expression of Ki67 by immunohistochemistry and correlated the findings with tumor histology and patient survival.
Results: Of the 21 patients studied, 12 over expressed antigen Ki67. There was no significant association between over expression of Ki67 and survival, although we observed a clinical association. Over expression of Ki67 correlated with more aggressive histology. Being under the age of 11 was a poor prognostic factor. Overall survival was 49% at 120 months.
Conclusions: Being young (under 11 years) is a marker of poor prognosis among pediatric patients with anaplasic astrocytoma or glioblastoma multiforme. Overexpression expression of antigen Ki67 is associated with histology and may be associated with poor survival among patients treated in our hospital.


REFERENCES

  1. Gurney J, Smith M, Bunin G. CNS and miscellaneous intracraneal and intraspinal neoplams En: Ries LAG, Smith MA, Gurney JG, editors. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. NIH Pub No 99-4649. Bethesda MD: National Cancer Institute, SEER Program; 1999. pp. 51-63.

  2. Dirección General de Epidemiología. Compendio del Registro Histopatológico de Neoplasias en México. Morbilidad, regionalización 1993-1996 y mortalidad. Tendencias 1985-1995. México: Secretaría de Salud; 1998.

  3. Sepúlveda-Vildósola AC, López-Aguilar E. Epidemiology of central nervous system tumors in children: report of the Mexican Brain Tumor Study Group. Pediatr Blood Cancer 2006;47:454.

  4. Dohrmann GJ, Farewell JR, Flannery JT. Astrocytomas in childhood: a population based study. Surg Neurol 1985;23:64-68.

  5. Halperin EC, Watson DM, George SL. Duration of symptoms prior to diagnosis is related inversely to presenting disease stage in children with medulloblastoma: a Pediatric Oncology Group Study. J Neuropathol Exp Neurol 2000;59:867-865.

  6. Starr A, Achor J. Auditory brain stem responses in neurological disease. Arch Neurol 1975;32:761-768.

  7. Omuro A, Leite C, Mokhtari K, Delattre J. Review. Pitfalls in the diagnosis of brain tumours. Lancet Neurol 2006;5:937-948.

  8. Yang P, Berger P, Cohen M, Duffner PK. Computed tomography and childhood seizure disorders. Neurology 1979;29:1084-1088.

  9. Vézina LG. Imaging of central nervous system tumors in children: advances and limitations. J Child Neurol 2008;23:1128-1135.

  10. Bloom HJG. Prospects for increasing survival in children with medulloblastoma: present and future studies. Mutildisciplin Aspects Brain Tumor Ther 1979;1:245-251.

  11. Cohen BH, Zeltzer PM, Boyett JM, Geyer JR, Allen JC, Finlay JL, et al. Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: A Children’s Cancer Group randomized trial. J Clin Oncol 1995;13:1687-1696.

  12. Nejat F, El Khashab M, Rutka J. Initial management of childhood brain tumors: neurosurgical considerations. J Child Neurol 2008;23:1136-1148.

  13. Ziegler DS, Cohn RJ, McCowage G, Álvaro F, Oswald C, Mrongovius R, et al. Efficacy of vincristine and etoposide with escalating cyclophosphamide in poor-prognosis pediatric brain tumors. Neuroncology 2006;8:53-59.

  14. López-Aguilar E, Sepúlveda-Vildósola AC, Rivera-Márquez H, Cerecedo-Díaz F, Valdés-Sánchez M, Delgado-Huerta S, et al. Preirradiation ifosfamide, carboplatin and etoposide (ICE) for the treatment of high-grade astrocytomas in children. Childs Nerv Syst 2003;19:818-823.

  15. Leibel SA, ScottCB, Loefler JS. Contemporary approaches to the treament of malignant gliomas. Semin Oncol 1994;21:126-131.

  16. López-Aguilar E, Cerecedo-Díaz F, Sepúlveda-Vildósola A, Rivera-Márquez H, Castellano-Toledo A, Arias-Gómez J, et al. Astrocitomas en pediatría. Factores pronósticos. Gac Med Mex 1997;133:231-235.

  17. López-Muñiz A, Gutiérrez JC, García-Fernández C, Herrero A. Valor pronóstico de los marcadores tumorales de proliferación celular y angiogénesis en los olidendrogliomas. Oncologia 2000;27:289-296.

  18. Gutmann DH, James CD, Poyhonen M, Louis DN, Ferner R, Guha A, et al. Molecular analysis of astrocytomas presenting after age 10 in individuals with NF1. Neurology2003;61:1397-1400.

  19. Thorp SH. Proliferative activity in human glioblastomas: evaluation of different Ki67 equivalent antibodies. J Mol Pathol 1997;50:198-200.

  20. Hilton D, Love S, Barber R, Ellison D, Sandeman DR. Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumours to radiotherapy. Neurosurgery 1998;42:724-729.

  21. Montine TJ, Vandersteenhoven JJ, Aguzzi A, Boyko OB, Dodge RK, Kerns BJ, et al. Prognostic significance of Ki-67 proliferation index in supratentorial fibrillary astrocytic neoplasms. Neurosurgery.1994; 34:674-679.

  22. Tihan T, Davis R, Elowitz E, DiCostanzo D, Moll U. Practical value of Ki-67 and P53 labelling indexes in stereotactic biopsies of diffuse and pilocytic astrocytomas. Arch Pathol Lab Med 2000;124:108-113.

  23. Johannsessen A, Thorp SH. The Clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol Oncol 2006;12:143-147.

  24. Isolan GR. Astrocytic neoplasms and correlation with mutate p53 and Ki-67 proteins. Arq Neuropsiquiatr 2005;63:997-1004.

  25. Heegaard S, Sommer HM, Broholm H, Broendstrup O. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer. 1995;76:1809-1813.

  26. Grotzer M, Janss A, Georger B, Zhao H, Rorke LB, Phillips PC. Prognostic significance of Ki 67 (M1B1) proliferation index in childhood primitive neuroectodermal tumours of the central nervous system. Med Pediatr Oncol 2001;36:268-273.

  27. Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathology 1990;17:489-503.

  28. Gerdes J, Schuan V, Lenke H. Prediction of a mouse monoclonal antibody reaction with a human nuclear antigen associated with cell proliferation. Int J Can 1983;31:13-20.

  29. Ellison DW, Steart PV, Bateman AC, Pickering RM, Palmer JD, Weller RO. Prognostic indicators in a range of astrocytic tumors: an immunohistochemical study with Ki-67 and p53 antibodies. J Neurol Neurosurg Psychiatry. 1995;59:413-419.

  30. Johanssen A, Etorp S. The clinical value of Ki67 in human astrocytomas. Pathol Oncol Res 2006;12:143-147.

  31. Pollack I, Ronald L. The relationship between TP53 mutations and overexpression of p53 and prognosis of maligant gliomas. Cancer Res 1997;57:304-309.

  32. Tihan T, Davis R, Elowitz E. Practical value of Ki67 and p53 level indexes in diffuse and pilocitic astrocitoma. Arch Pathol Lab Med 2000; 124:108-113.

  33. Faury D, Nantel A, Dunn SE, Guiot MC, Haque T, Hauser P, et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol 2007;25:1196-1208.




2020     |     www.medigraphic.com